Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy

Contributed by: Business Wire

Logo

Tags

Professional Services

Health

Infectious Diseases

Other Professional Services

Pharmaceutical

Biotechnology

MPM BioImpact

More Like This

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

Nihon Medi-Physics headquarters and woman looking at molecular imaging images (Photo: Business Wire)

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

GlobeNewswire associated0

Development Bank of Japan invests in 4BIO Capital’s Ventures III fund

PR Newswire associated0

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

PR Newswire associated0

LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital